Asymmetrex, LLC is a for-profit limited liability company with a mission of advancing innovative adult tissue stem cell technologies to applications in stem cell medicine and drug development.
Asymmetrex's current lead technology and product is a first-in-class technology for counting adult tissue stem cells in complex research preparations and stem cell transplantation treatment preparations.
The AlphaSTEM Test^TM technology is available for use to determine, for the first time, the dose of active therapeutic adult tissue stem cells in treatment samples like umbilical cord blood, bone marrow, mobilized peripheral blood, and amniotic fluid. To date, the AlphaSTEM Test^TM has been validated for counting stem cells from human lung, liver, hematopoietic (bone marrow-derived and umbilical cord blood-derived), and mesenchymal (including cells derived from bone marrow, umbilical cord stroma, and amniotic fluid) tissues.
The AlphaSTEM Test^TM also provides a powerful new assay for drug safety evaluations by pharmaceutical companies. It provides less expensive and earlier detection of drug candidates that will induce chronic organ failure. About half of drugs that fail due to safety in phase II trials, do so because of tissue stem cell toxicity that results in chronic organ failure.
The AlphaSTEM Test^TM can provide essential data on the number and quality of tissue stem cells in the transplant treatment preparations of regenerative medicine and gene editing companies; and it could be used to identify agents that increase the efficacy of stem cell transplantation treatments. The ability to count tissue stem cells and simulation their cell kinetics allows Asymmetrex to rapidly design procedures for optimizing the expansion of tissue stem cells in culture. This capability can dramatically reduce the cost of stem cell production, by as much as 95%.
Asymmetrex is also the developer and holder of a rich portfolio of recently issued patents for biotechnologies for the quantification and production of human adult tissue stem cells, including cancer stem cells. These patents are available for licensing to enable the regenerative medicine goals of licensee companies.
Another significant interest of the company is development is an FDA-approved cGMP manufacturing process for large-scale production of normal human liver stem cells for applications in pharmaceutical drug candidate evaluations and for supply of stem cell-renewable human liver hepatocytes for extracorporeal liver assist devices (ELADs).
Currently, Asymmetrex markets proprietary renewable rodent and human adult tissue stem cell strains for research purposes with its distribution partner KeraFAST. The patented technologies that produced these cell strains, including pancreatic stem cells and hair follicle stem cells, are available for licensing in collaborative development agreements.
Nov 18, 2020
Posted by Asymmetrex, LLC